Arcutis Biotherapeutics, Inc. ARQT R2K
Healthcare · Biotechnology · United States
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
READ MORE ›$21.46
+64.57% 1Y
Market & Price
Market Cap
$2.68B
Current Price
$21.46
High / Low (52W)
$31.20 / $13.04
Beta
1.59
Valuation
Stock P/E
-
Industry PE
23.65
Forward P/E
18.57
PEG Ratio
-
Book Value
$1.52
Price to Book
14.15
P/S
6.46
EV/EBITDA
471.35
Dividend Yield
-
Profitability & Returns
ROCE
-0.95%
ROE
-1.43%
ROA
0.50%
Profit Margin
-0.57%
Op Margin
-8.62%
EPS (Latest Qtr)
$-0.09
EPS (TTM)
$-0.02
Balance Sheet & Liquidity
Debt/Equity
0.60
Quick Ratio
2.26
Current Ratio
2.68
Debt
$114.67M
Total Assets
$432.97M
Current Assets
$411.23M
Working Capital
$281.39M
Ownership
Promoter Holding
1.76%
Chg in Prom Hold
-
FII / Inst Holding
109.97%
Chg in FII Hold
0.00%
Financial Snapshot
Enterprise Value
$2.57B
Total Revenue (TTM)
$415.62M
EBITDA
$5.46M
Free Cash Flow
$3.53M
Operating Cash Flow
$26.99M
Shares Outstanding
125.08M
Gross Margin
90.94%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
367.27%
Profit 5Y
31.61%
Revenue (YoY)
60.10%
Earnings (YoY)
-
PROS
- Compounding revenue at 367.3% over 5 years.
- Profit CAGR of 31.6% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 31.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ARQT Arcutis Biotherapeutics, Inc. R2K | 21.46 | - | $2.68B | - | -0.95% | -1.43% | 367.27% | 31.61% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | 2.78M | 5.19M | 38.11M | 49.57M | 30.86M | 44.76M | 65.85M | 81.50M | 99.22M | 129.50M | 105.40M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.83M | 7.49M | 8.69M | 11.69M | 9.78M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.02M | 74.01M | 90.53M | 117.81M | 95.61M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 81.55M | 88.62M | 82.01M | 99.43M | 104.70M |
| Operating Income | -6.95M | -8.54M | -14.65M | - | -28.65M | -35.63M | -38.30M | - | -36.09M | -42.08M | -57.08M | -62.63M | -65.83M | -104.75M | -76.27M | -66.76M | -36.90M | -31.62M | -50.08M | -39.07M | -24.53M | -14.61M | 8.53M | 18.39M | -9.09M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.82M | -11.95M | 11.12M | 21.43M | -6.27M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.98M | 3.03M | 3.07M | 3.00M | 4.37M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -24.78M | -15.54M | 7.49M | 17.86M | -11.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 279.00K | 342.00K | 80.00K | 470.00K | 93.00K |
| Net Income | -6.66M | -8.29M | -14.48M | -12.57M | -28.01M | -35.41M | -38.20M | -34.05M | -36.04M | -42.01M | -56.98M | -64.32M | -67.41M | -107.71M | -80.10M | -70.99M | -44.77M | -35.38M | -52.33M | -41.54M | -25.06M | -15.89M | 7.41M | 17.39M | -11.29M |
| Diluted EPS | - | - | - | - | - | -0.94 | -1.01 | - | -0.76 | -0.84 | -1.14 | -1.27 | -1.31 | -1.89 | -1.31 | -1.16 | -0.73 | -0.32 | -0.42 | -0.33 | -0.20 | -0.13 | 0.06 | 0.13 | -0.09 |
| R&D Expense | 6.20M | 7.21M | 12.35M | - | 25.18M | 30.01M | 32.74M | - | 21.63M | 30.77M | 40.60M | 40.62M | 38.20M | 69.73M | 35.34M | 25.22M | 26.24M | 23.14M | 19.30M | 19.50M | 17.54M | 19.45M | 19.60M | - | 30.63M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 3.69M | 59.61M | 196.54M | 376.07M |
| Cost of Revenue | - | - | - | - | 754.00K | 4.99M | 19.13M | 36.70M |
| Gross Profit | - | - | - | - | 2.93M | 54.62M | 177.41M | 339.38M |
| Operating Expenses | - | - | - | - | 304.56M | 295.72M | 305.81M | 351.60M |
| Operating Income | -19.73M | -43.13M | -136.65M | - | -301.63M | -241.10M | -128.40M | -12.23M |
| EBITDA | - | - | - | - | -294.87M | -228.56M | -110.27M | 1.78M |
| Interest Expense | - | - | - | - | 15.65M | 29.71M | 27.17M | 12.08M |
| Pretax Income | - | - | - | - | -311.46M | -259.03M | -139.39M | -14.97M |
| Tax Provision | - | - | - | - | 0 | 3.11M | 647.00K | 1.17M |
| Net Income | -19.25M | -42.00M | -135.68M | - | -311.46M | -262.14M | -140.04M | -16.14M |
| Diluted EPS | - | -22.78 | -3.80 | - | -5.66 | -3.78 | -1.16 | -0.13 |
| R&D Expense | 17.94M | 36.52M | 115.31M | 145.56M | 182.44M | 110.58M | 76.42M | 77.05M |
Compounded Sales Growth
| 5 Years: | 367.27% |
| 1 Year: | 60.10% |
Compounded Profit Growth
| 5 Years: | 31.61% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +64.57% |
| 6 Months: | -30.17% |
| 3 Months: | -20.43% |
| 1 Month: | -4.07% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 107.01M | 298.27M | - | 449.27M | 341.37M | 348.89M | 432.97M |
| Current Assets | - | - | - | - | - | 437.41M | 330.43M | 335.82M | 411.23M |
| Cash & Equivalents | - | - | 63.34M | 65.08M | - | 53.64M | 88.40M | 71.33M | 42.91M |
| Inventory | - | - | - | - | - | 7.51M | 13.13M | 14.53M | 22.63M |
| Receivables | - | - | - | - | - | 8.46M | 25.81M | 73.07M | 146.23M |
| Total Liabilities | - | - | 5.55M | 27.65M | - | 239.69M | 252.70M | 191.35M | 243.49M |
| Current Liabilities | - | - | 5.24M | 22.60M | - | 37.81M | 46.67M | 81.01M | 129.84M |
| Long Term Debt | - | - | - | 0 | - | 197.77M | 201.80M | 107.20M | 107.96M |
| Total Debt | - | - | - | - | - | 202.54M | 205.92M | 109.77M | 114.22M |
| Total Equity | -4.99M | -23.99M | -65.03M | 270.62M | - | 209.58M | 88.67M | 157.54M | 189.48M |
| Shares Outstanding | - | - | - | - | - | 61.04M | 96.79M | 117.85M | 123.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -14.09M | -42.84M | -113.03M | - | -257.71M | -247.06M | -112.16M | -5.62M |
| Investing Cash Flow | -11.53M | -26.32M | -181.82M | - | -87.20M | 180.23M | 28.82M | -30.25M |
| Financing Cash Flow | 61.59M | 93.10M | 298.14M | - | 301.80M | 101.32M | 66.20M | 6.97M |
| Capital Expenditure | -0 | -295.00K | -321.00K | - | -23.28M | -428.00K | -5.14M | -10.69M |
| Free Cash Flow | -14.09M | -43.13M | -113.35M | - | -281.00M | -247.49M | -117.30M | -16.31M |
| Net Change in Cash | - | - | - | - | -43.12M | 34.50M | -17.14M | -28.91M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | 79.5% | 91.6% | 90.3% | 90.2% |
| Operating Margin % | - | - | - | - | -8,183.0% | -404.5% | -65.3% | -3.3% |
| Net Margin % | - | - | - | - | -8,449.8% | -439.8% | -71.3% | -4.3% |
| ROE % | 80.3% | 64.6% | -50.1% | - | -148.6% | -295.6% | -88.9% | -8.5% |
| ROCE % | - | -42.4% | -49.6% | - | -73.3% | -81.8% | -47.9% | -4.0% |
Shareholding Pattern
Insiders
1.76%
Institutions
109.97%
Public Float
111.94%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Suvretta Capital Management, LLC | 9.86% | 12.33M | $264.54M |
| 2 | Frazier Life Sciences Management, L.P. | 7.89% | 9.87M | $211.91M |
| 3 | Blackrock Inc. | 7.36% | 9.20M | $197.44M |
| 4 | Rubric Capital Management LP | 6.61% | 8.27M | $177.51M |
| 5 | State Street Corporation | 5.03% | 6.30M | $135.12M |
| 6 | Polar Capital Holdings PLC | 4.53% | 5.67M | $121.61M |
| 7 | Jennison Associates LLC | 3.98% | 4.98M | $106.89M |
| 8 | Vanguard Capital Management LLC | 3.89% | 4.87M | $104.54M |
| 9 | Gilder Gagnon Howe & Co LLC | 3.44% | 4.30M | $92.36M |
| 10 | Morgan Stanley | 3.37% | 4.22M | $90.54M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ARQT
No recent headlines available.